Contract award notice

Results of the procurement procedure

Section I: Contracting entity

I.1) Name and addresses

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.2) Description

Section IV: Procedure

IV.1) Description

Section V: Award of contract

Contract No: CAV-DAP2 (26-27) 18

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

20/05/2026

V.2.2) Information about tenders

Number of tenders received: 1

Number of tenders received from SMEs: 1

Number of tenders received from tenderers from EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 0

Number of tenders received by electronic means: 0

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot:

Total value of the contract/lot: : 274 200.00  GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 02/06/2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR Wales.

Providers should send their written representation during the standstill period to Sam.Davies8@wales.nhs.uk

The Cardiff and Vale University Health Board intends to utilise Direct Award Process 2 under the Provider Selection Regime (Wales) to award a contract for the provision of Mobile Lithotripsy Services to the incumbent provider.

- No providers were excluded from this Procurement

- There were no declared conflicts of individuals making the decision

- There is no information withheld under regulation 23 (1)

1. Applicability of Direct Award Process 2

Direct Award Process 2 is considered appropriate where:

· The existing provider is delivering services to an acceptable standard, and

· Changing provider would likely result in disruption, reduced quality, or disproportionate costs/risk, and

· The service is of a nature where continuity and integration are critical to patient outcomes.

The current service provided by the incumbent provider meets these criteria.

2. Performance of Current Provider

The incumbent provider has:

· Consistently delivered safe, high-quality lithotripsy services in line with clinical requirements

· Demonstrated strong clinical outcomes and patient satisfaction

· Maintained compliance with all contractual KPIs and governance standards

· Established effective clinical integration with Urology, Radiology, and surgical teams.

There are no significant performance concerns that would justify market testing at this time.

3. Continuity of Care and Clinical Integration

Mobile Lithotripsy is a highly specialised, pathway critical service, requiring:

· Integration with pre and post procedure diagnostic pathways

· Coordination with theatre scheduling, imaging, and urology clinics

· Established clinical protocols and multidisciplinary working

A change in provider would introduce:

· Risk of service disruption and delays in treatment

· Loss of embedded processes and clinical familiarity

· Potential impact on waiting time performance and patient outcomes

Maintaining the current provider supports continuity of care and pathway stability.

4. Technical and Operational Considerations

The incumbent provider:

· Supplies specialist mobile equipment aligned with site infrastructure

· Provides experienced clinical and technical staff familiar with local systems

· Has established operational logistics for mobile unit deployment

Transitioning to a new provider would require:

· Equipment validation and compatibility checks

· Staff onboarding and training

· Reconfiguration of operational pathways

This would result in avoidable cost, delay, and operational risk.

5. Value for Money

The current arrangement:

· Provides demonstratable value for money

· Avoids mobilisation costs associated with a new provider

· Minimises inefficiencies during transaction period

A competitive process is unlikely to delivery significantly improved value when factoring in transition risks and costs.

6. Patient Impact

Maintaining the current provider supports:

· Timely access to treatment, reducing waiting list pressures

· Continuity in patient experience and clinical outcomes

· Minimisation of clinical risk associated with change

(WA Ref:164966)

VI.4) Procedures for review

VI.5) Date of dispatch of this notice

20/05/2026